Aptinyx ‘s $117.5 Million Initial Public Offering

Goodwin advised Aptinyx on the transaction Aptinyx (“APTX”), a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, closed its public offering of 7,359,998 shares...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here